{"id":214284,"date":"2025-05-19T14:03:52","date_gmt":"2025-05-19T19:03:52","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2025\/05\/amiloride-found-to-be-as-effective-as-spironolactone-in-managing-resistant-hypertension"},"modified":"2025-05-19T14:03:52","modified_gmt":"2025-05-19T19:03:52","slug":"amiloride-found-to-be-as-effective-as-spironolactone-in-managing-resistant-hypertension","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2025\/05\/amiloride-found-to-be-as-effective-as-spironolactone-in-managing-resistant-hypertension","title":{"rendered":"Amiloride found to be as effective as spironolactone in managing resistant hypertension"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/amiloride-found-to-be-as-effective-as-spironolactone-in-managing-resistant-hypertension2.jpg\"><\/a><\/p>\n<p>Yonsei University College of Medicine-led research has shown amiloride is as effective as spironolactone in reducing systolic blood pressure (SBP) over 12 weeks in patients with resistant hypertension.<\/p>\n<p>Resistant <a href=\"https:\/\/medicalxpress.com\/tags\/hypertension\/\" rel=\"tag\" class=\"\">hypertension<\/a> affects approximately 10% of hypertensive patients and is associated with worse outcomes than nonresistant cases.<\/p>\n<p>Spironolactone is a fourth-line medication, introduced only after renin-angiotensin system inhibitors, <a href=\"https:\/\/medicalxpress.com\/tags\/calcium+channel+blockers\/\" rel=\"tag\" class=\"\">calcium channel blockers<\/a>, and thiazide diuretics fail to control blood pressure. Adverse effects, particularly hyperkalemia and hormonal disruptions, limit its use in long-term care. Amiloride, a potassium-sparing diuretic, lacks these hormonal side effects, making it a potential replacement candidate.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Yonsei University College of Medicine-led research has shown amiloride is as effective as spironolactone in reducing systolic blood pressure (SBP) over 12 weeks in patients with resistant hypertension. Resistant hypertension affects approximately 10% of hypertensive patients and is associated with worse outcomes than nonresistant cases. Spironolactone is a fourth-line medication, introduced only after renin-angiotensin system [\u2026]<\/p>\n","protected":false},"author":732,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11],"tags":[],"class_list":["post-214284","post","type-post","status-publish","format-standard","hentry","category-biotech-medical"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/214284","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/732"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=214284"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/214284\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=214284"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=214284"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=214284"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}